AXL and non-small cell lung carcinoma: Moreover, a high number of AXL-targeted monoclonal antibodies, such as hMAb173 for renal cell carcinoma22, D9 and E8 for pancreatic cancer23, and YW327.6S2 for NSCLC and breast cancer24, have shown anticancer efficacy in preclinical and earlier clinical trial stages16,17.